AVR Share Price Performance
Recent AVR News & Updates
No updates
Anteris Technologies Global Corp. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.27
- Gross Margin
- 53.03%
- Net Profit Margin
- -3,281.39%
- Debt/Equity Ratio
- 1.7%
Anteris Technologies Global Corp. Competitors
About AVR
- Founded
- n/a
- Employees
- 136
- CEO
- WebsiteView website
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
Australian Market Performance
- 7 Days: -0.2%
- 3 Months: 5.6%
- 1 Year: 8.6%
- Year to Date: 5.1%
In the last week, the market has been flat, with a notable exception in the Materials sector dropping 4.2%. Meanwhile, the market is actually up 8.6% over the past year. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading